Caterina Giovagnoni

CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease

M. Mielke, H. D. de Vries, J. Walter, 2020, Alzheimer's research & therapy.

FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4.

J. Swinnen, H. D. de Vries, J. Walter, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Immunofluorescence Labeling of Lipid-Binding Proteins CERTs to Monitor Lipid Raft Dynamics.

M. Losen, P. Martinez-Martinez, S. Crivelli, 2021, Methods in molecular biology.

CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease

M. Mielke, H. D. de Vries, J. Walter, 2020, Alzheimer's Research & Therapy.

Function of ceramide transfer protein for biogenesis and sphingolipid composition of extracellular vesicles

Lu Zhang, Zhihui Zhu, P. Martinez-Martinez, 2022, Journal of extracellular vesicles.

Sphingolipids in Alzheimer's disease, how can we target them?

H. D. de Vries, J. Walter, M. Losen, 2020, Advanced drug delivery reviews.

Altered sphingolipid function in Alzheimer's disease; a gene regulatory network approach

A. del Sol, J. Kleinjans, E. Glaab, 2021, Neurobiology of Aging.

Ceramide analog [18F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimer’s disease transgenic mice by functioning as a metabolic probe

F. Mottaghy, J. Swinnen, H. D. de Vries, 2020, Scientific Reports.